In the dynamic field of gene therapy, understanding the complexities of Adeno-Associated virus (AAV) immunogenicity is crucial for achieving success. Managing pre-existing neutralizing antibodies (NAbs) and Total Antibodies (TAbs) toward AAV capsids poses a significant challenge, potentially compromising treatment outcomes with recombinant vectors.
Recombinant vectors aim for precise gene delivery, yet success depends on overcoming immune barriers, especially pre-existing antibodies recognizing AAV capsids. These antibodies can impede successful gene transfer, hindering therapeutic payload delivery to target cells.